| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/11/2011 | CA2577310C Methods and compositions for oral delivery of fts |
| 01/11/2011 | CA2472149C New fluorenecarboxylic acid esters, process for the manufacture thereof and use thereof as medicaments |
| 01/11/2011 | CA2461623C Water-in-oil emulsions with ethylene oxide groups, compostions, and methods |
| 01/11/2011 | CA2453974C 4-(benzylideneamino)-3-(methylsulfanyl)-4h-1,2,4-triazin-5-one derivatives having a pde iv-inhibiting and tnf-antagonistic action for the treatment of heart diseases and allergies |
| 01/11/2011 | CA2451678C Azaindoles |
| 01/11/2011 | CA2387095C Compound with growth hormone releasing properties |
| 01/11/2011 | CA2328990C N,n-disubstituted amides that inhibit the binding of integrins to their receptors |
| 01/11/2011 | CA2309541C Vegi, an inhibitor of angiogenesis and tumor growth |
| 01/11/2011 | CA2286313C Novel ldl-receptor |
| 01/11/2011 | CA2218764C Vaccine composition containing polyribosylribitol phosphate and method for making same |
| 01/06/2011 | WO2011003018A2 Halogenated 2-deoxy-lactones, 2'-deoxy--nucleosides, and derivatives thereof |
| 01/06/2011 | WO2011001097A1 Dermaseptin b2 used as an inhibitor of the growth of a tumor |
| 01/06/2011 | WO2011000621A1 Infant cereal comprising non-replicating probiotic microorganisms |
| 01/06/2011 | WO2011000124A1 Pharmaceutical composition including viable probiotic strains of lactobacillus spp. used for the prevention and recovery of individuals with urinary tract infections and immunocompromised individuals |
| 01/06/2011 | WO2011000058A1 A method of preparation of a biological particulate structure |
| 01/06/2011 | WO2010119102A3 Pharmaceutical composition containing proton pump inhibitor for treating dermatological autoimmune diseases |
| 01/06/2011 | WO2010099444A3 Modified live aeromonas hydrophila vaccine for aquatic animals |
| 01/06/2011 | WO2010099432A3 Recognition of cyp2e1 epitopes |
| 01/06/2011 | WO2010083277A3 Methods for improving hepatic and immune function in an animal |
| 01/06/2011 | WO2010056985A8 Treatment of proteinopathies using a farnesyl transferase inhibitor |
| 01/06/2011 | WO2009007849A3 Il-23 receptor antagonists and uses thereof |
| 01/06/2011 | US20110004949 Immunoglobulin 1 |
| 01/06/2011 | US20110004948 Immunoglobulin 2 |
| 01/06/2011 | US20110004164 Non-sedating antihistamine injection formulations and methods of use thereof |
| 01/06/2011 | US20110004000 Mitotic Kinesin Inhibitor |
| 01/06/2011 | US20110003888 Hops extraction methods and mixtures |
| 01/06/2011 | US20110003885 Methods and compositions for inhibition of immune responses and autoimmunity |
| 01/06/2011 | US20110003877 SMAC Mimetic |
| 01/06/2011 | US20110003853 Metalloproteinase Inhibitors |
| 01/06/2011 | US20110003851 Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors |
| 01/06/2011 | US20110003824 Caspase Inhibitors and Uses Thereof |
| 01/06/2011 | US20110003806 Heteroaryls and uses thereof |
| 01/06/2011 | US20110003799 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators |
| 01/06/2011 | US20110003798 Compounds and compositions as kinase inhibitors |
| 01/06/2011 | US20110003797 HEXAHYDROCYCLOPENTYL[f]INDAZOLE CARBOXAMIDES AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
| 01/06/2011 | US20110003792 Anti-inflammatory agents |
| 01/06/2011 | US20110003790 Pyrido [4, 3-d] pyrimidinone derivatives as kinase inhibitors |
| 01/06/2011 | US20110003781 Non-Sedating Antihistamine Injection Formulations and Methods of Use Thereof |
| 01/06/2011 | US20110003766 Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as a2ar agonists |
| 01/06/2011 | US20110003765 Substituted 4--piperidine-1-carboxylic acid esters as a2ar agonists |
| 01/06/2011 | US20110003756 C5a Receptor Antagonists |
| 01/06/2011 | US20110003751 Novel Immunoregulatory Peptides, Compositions and Uses Thereof |
| 01/06/2011 | US20110003750 Human 3 relaxin |
| 01/06/2011 | US20110003388 processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient; making an enhanced, autologous fat graft comprising supplementing a first portion of extracted adipose tissue with an additive and a disaggregated population of adipose-derived cells |
| 01/06/2011 | US20110003015 Stabilized composition comprising at least one adrenergic compound |
| 01/06/2011 | US20110003009 Process for obtaining a rabbit skin comprising biological active substances |
| 01/06/2011 | US20110002994 Method of regulating the th17 pathway and its associated metabolic impact |
| 01/06/2011 | US20110002983 Compound |
| 01/06/2011 | US20110002980 Vaccines using nucleic acid-lipid complexes |
| 01/06/2011 | US20110002964 Methods for cancer treatment using stem cells |
| 01/06/2011 | US20110002961 Interleukin 12 paracrine gene delivery enhanced CTL immunotherapy |
| 01/06/2011 | US20110002956 Mutant human cd80 and compositions for and methods of making and using the same |
| 01/06/2011 | US20110002953 Use of immidazoquinolinamines as adjuvants in dna vaccination |
| 01/06/2011 | US20110002952 FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF |
| 01/06/2011 | US20110002946 Immunostimulatory Combinations |
| 01/06/2011 | US20110002943 Use of enterovirus for diagnostics, treatment and prevention of disease |
| 01/06/2011 | US20110002942 Engineered Anti-IL-23 Antibodies |
| 01/06/2011 | US20110002939 monoclonal antibody and a method thereof |
| 01/06/2011 | US20110002938 Hematopoietic cells expressing the protein krtcap3 and ligands for the protein krtcap3 |
| 01/06/2011 | US20110002936 Anti-IL-6/IL-6R Antibodies and Methods of Use Thereof |
| 01/06/2011 | US20110002913 Use of interleukin-4 antagonists and compositions thereof |
| 01/06/2011 | US20110002901 Bacterial strain having anti-allergic activity, and beverage, food and anti-allergic agent comprising cell of the bacterial strain |
| 01/06/2011 | US20110002899 Lymph Nodes as a Site for Regeneration |
| 01/06/2011 | US20110002888 Albumin Fusion Proteins |
| 01/06/2011 | US20110002887 Combinations of antibodies selective for dr5 and other therapeutic agents |
| 01/06/2011 | US20110002881 Treatment and prophylaxis |
| 01/06/2011 | US20110002851 Cationic Colloidal Carriers for Delivery of Active Agents to the Blood-Brain Barrier in the Course of Neuroinflammatory Diseases |
| 01/06/2011 | US20110000480 Administration of interferon for prophylaxis against or treatment of pathogenic infection |
| 01/06/2011 | CA2803987A1 Non-sedating antihistamine injection formulations and methods of use thereof |
| 01/06/2011 | CA2767012A1 Dermaseptin b2 used as an inhibitor of the growth of a tumor |
| 01/06/2011 | CA2766899A1 Compositions and methods for diagnosing and/or treating influenza infection |
| 01/06/2011 | CA2766805A1 Hyr1 as a target for active and passive immunization against candida |
| 01/06/2011 | CA2766770A1 Novel antibodies and their uses in therapeutic and diagnostic methods |
| 01/06/2011 | CA2766162A1 Smac mimetic |
| 01/05/2011 | EP2270164A2 Recombinant protein variants |
| 01/05/2011 | EP2270144A1 Partial peptide of survivin presented on mhc class ii molecule and use thereof |
| 01/05/2011 | EP2270137A1 Method for producing cells having characteristic of hematopoietic stem cells/progenitor cells |
| 01/05/2011 | EP2270052A2 Antibodies to OPGL |
| 01/05/2011 | EP2270050A1 Anti-CD19 antibodies with reduced immunogenicity |
| 01/05/2011 | EP2270049A2 Recombinant anti-interleukin-9-antibody |
| 01/05/2011 | EP2270047A2 Anti-C5 antibodies and their therapeutic uses |
| 01/05/2011 | EP2270046A2 Methods and compositions for the treatment of hemolysis-associated diseases |
| 01/05/2011 | EP2270005A1 Prodrug of an ice inhibitor |
| 01/05/2011 | EP2270004A1 Caspase inhibitors and uses thereof |
| 01/05/2011 | EP2269656A2 Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment |
| 01/05/2011 | EP2269654A2 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 01/05/2011 | EP2269651A2 Stabilisation of macrolides |
| 01/05/2011 | EP2269643A2 Hcv vaccine compositions |
| 01/05/2011 | EP2269642A2 Hcv vaccine compositions |
| 01/05/2011 | EP2269641A2 Hcv vaccine compositions |
| 01/05/2011 | EP2269640A2 Hcv vaccine compositions |
| 01/05/2011 | EP2269616A2 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 01/05/2011 | EP2268618A1 Compounds and compositions as tlr activity modulators |
| 01/05/2011 | EP2268611A2 Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
| 01/05/2011 | EP2268603A1 Process for the preparation of 2-amino-2- [2- (4-c3-c21-alkyl-phenyl)ethyl]propane-1, 3-diols |
| 01/05/2011 | EP2268295A2 Activation of innate and adaptive immune responses by a ginseng extract |
| 01/05/2011 | EP2268293A2 Stem cell composition for inducing transplant tolerance |
| 01/05/2011 | EP2146974B1 N- hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidine 2 ethansulfonic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same |
| 01/05/2011 | EP2069404B1 Humanized anti-cd100 antibodies |
| 01/05/2011 | EP1720572B1 Monovalent ligand of the fcalphari receptor as an anti-inflammatory agent |